Abstract | STUDY OBJECTIVES: METHODS: This double-blind, parallel-group, randomized, placebo-controlled trial in 24 participants was conducted at the Stanford Sleep Center. Patients were adults with definite iRBD or Parkinson's disease and probable RBD (PD-RBD), and persistence of ≥ 2 weekly episodes despite standard therapy. Patients were randomized 1:1 to receive SXB during a 4-week titration followed by a 4-week stable dosing period. Primary outcome was number of monthly RBD episodes according to a diary filled by patients and partners. Secondary outcomes were severity, number of severe RBD episodes, and objective RBD activity on video polysomnography. RESULTS: Twelve iRBD and 12 PD-RBD participated (mean 65.8 years), and 22 (n = 10 SXB, 12 placebo) completed the study. Although no significant between-group difference was found, SXB showed reduction of monthly RBD episodes by 23.1 (95% CI -36.0, -10.2; p = 0.001) versus 10.5 with placebo (95% CI, -22.6, 1.6; p = 0.087). Improvement from baseline was similarly observed for RBD overall severity burden (each episode weighted for severity), number of severe episodes, and objective RBD activity per video-polysomnography. Two participants receiving SXB withdrew due to anxiety and dizziness. The majority of adverse events are otherwise resolved with dose adjustment. CONCLUSION: SXB could reduce RBD symptoms; however, response was inconsistent and a large placebo effect was observed across patient-reported outcomes. Larger studies using objective endpoints are needed. CLINICAL TRIAL:
|
Authors | Emmanuel H During, Beatriz Hernandez, Mitchell G Miglis, Oliver Sum-Ping, Anahid Hekmat, Ana Cahuas, Adrian Ekelmans, Fuyumi Yoshino, Emmanuel Mignot, Clete A Kushida |
Journal | Sleep
(Sleep)
Vol. 46
Issue 8
(08 14 2023)
ISSN: 1550-9109 [Electronic] United States |
PMID | 37052688
(Publication Type: Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © Sleep Research Society 2023. Published by Oxford University Press on behalf of the Sleep Research Society. |
Chemical References |
|
Topics |
- Adult
- Humans
- REM Sleep Behavior Disorder
(complications, drug therapy)
- Sodium Oxybate
(therapeutic use)
- Sleep
- Anxiety
- Anxiety Disorders
|